APA (7th ed.) Citation

Li, X., Bi, M., Su, C., Fang, Y., WANG, Z., Yuan, Y., . . . Li, Y. (2023). Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment. Journal of clinical oncology, 41(16_suppl), 8585. https://doi.org/10.1200/JCO.2023.41.16_suppl.8585

Chicago Style (17th ed.) Citation

Li, Xingya, Minghong Bi, Chunxia Su, Yong Fang, Zibing WANG, Ying Yuan, Xiuping Du, Tangfeng Lv, and Yingyin Li. "Phase Ib/IIa Study Assessing the Safety and Efficacy of AL8326 Monotherapy in Patients with ≥3rd Line Small Cell Lung Cancer (SCLC) Treatment." Journal of Clinical Oncology 41, no. 16_suppl (2023): 8585. https://doi.org/10.1200/JCO.2023.41.16_suppl.8585.

MLA (9th ed.) Citation

Li, Xingya, et al. "Phase Ib/IIa Study Assessing the Safety and Efficacy of AL8326 Monotherapy in Patients with ≥3rd Line Small Cell Lung Cancer (SCLC) Treatment." Journal of Clinical Oncology, vol. 41, no. 16_suppl, 2023, p. 8585, https://doi.org/10.1200/JCO.2023.41.16_suppl.8585.